Medpace Holdings, Inc. (MEDP)
USD 331.0
(-5.02%)
USD 331.0
(-5.02%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 282.81 Million USD | 15.33% |
| 2022 | 245.21 Million USD | 35.18% |
| 2021 | 181.39 Million USD | 25.16% |
| 2020 | 144.92 Million USD | 44.69% |
| 2019 | 100.16 Million USD | 37.41% |
| 2018 | 72.89 Million USD | 86.75% |
| 2017 | 39.03 Million USD | 191.46% |
| 2016 | 13.39 Million USD | 254.41% |
| 2015 | -8.67 Million USD | 44.3% |
| 2014 | -15.57 Million USD | -162.68% |
| 2013 | 24.84 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 96.42 Million USD | 9.14% |
| 2024 Q2 | 88.35 Million USD | -13.84% |
| 2024 Q1 | 102.54 Million USD | 31.06% |
| 2023 Q3 | 70.5 Million USD | 15.53% |
| 2023 Q2 | 61.02 Million USD | -16.22% |
| 2023 Q1 | 72.84 Million USD | 6.15% |
| 2023 FY | 282.81 Million USD | 15.26% |
| 2023 Q4 | 78.24 Million USD | 10.98% |
| 2022 Q3 | 65.98 Million USD | 33.76% |
| 2022 Q1 | 61.27 Million USD | 22.56% |
| 2022 FY | 245.36 Million USD | 34.93% |
| 2022 Q4 | 68.62 Million USD | 4.0% |
| 2022 Q2 | 49.32 Million USD | -19.5% |
| 2021 Q1 | 43.16 Million USD | -14.79% |
| 2021 FY | 181.84 Million USD | 25.08% |
| 2021 Q2 | 39.8 Million USD | -7.78% |
| 2021 Q4 | 49.99 Million USD | 3.25% |
| 2021 Q3 | 48.42 Million USD | 21.64% |
| 2020 Q3 | 41.32 Million USD | 71.91% |
| 2020 FY | 145.38 Million USD | 44.74% |
| 2020 Q4 | 50.65 Million USD | 22.59% |
| 2020 Q2 | 24.03 Million USD | -16.76% |
| 2020 Q1 | 28.87 Million USD | -2.88% |
| 2019 Q1 | 19.14 Million USD | -15.58% |
| 2019 FY | 100.44 Million USD | 37.25% |
| 2019 Q4 | 29.73 Million USD | 24.34% |
| 2019 Q3 | 23.91 Million USD | -12.66% |
| 2019 Q2 | 27.37 Million USD | 43.02% |
| 2018 Q3 | 19.22 Million USD | 16.53% |
| 2018 FY | 73.18 Million USD | 87.07% |
| 2018 Q4 | 22.67 Million USD | 17.92% |
| 2018 Q2 | 16.5 Million USD | 13.87% |
| 2018 Q1 | 14.49 Million USD | 28.89% |
| 2017 Q4 | 11.24 Million USD | 14.55% |
| 2017 Q3 | 9.81 Million USD | 2.74% |
| 2017 Q2 | 9.55 Million USD | 13.25% |
| 2017 Q1 | 8.43 Million USD | 40266.67% |
| 2017 FY | 39.12 Million USD | 191.41% |
| 2016 Q3 | 5.03 Million USD | 1.49% |
| 2016 Q4 | -21 Thousand USD | -100.42% |
| 2016 FY | 13.42 Million USD | 254.79% |
| 2016 Q2 | 4.96 Million USD | 43.91% |
| 2016 Q1 | 3.44 Million USD | 140.21% |
| 2015 Q4 | -8.57 Million USD | -6348.12% |
| 2015 Q3 | -133 Thousand USD | -240.0% |
| 2015 Q2 | 95 Thousand USD | 261.02% |
| 2015 Q1 | -59 Thousand USD | 0.0% |
| 2015 FY | -8.67 Million USD | 44.3% |
| 2014 FY | -15.57 Million USD | -162.68% |
| 2014 Q1 | -1.23 Million USD | 0.0% |
| 2013 FY | 24.84 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -232.49 Million USD | 221.642% |
| Prenetics Global Limited | -62.72 Million USD | 550.881% |
| Star Equity Holdings, Inc. | -1.54 Million USD | 18369.38% |
| CareDx, Inc | -190.28 Million USD | 248.625% |
| Exact Sciences Corporation | -204.14 Million USD | 238.531% |
| Exagen Inc. | -23.68 Million USD | 1293.845% |
| Inotiv, Inc. | -105.14 Million USD | 368.984% |
| Guardant Health, Inc. | -479.44 Million USD | 158.986% |
| Biodesix, Inc. | -52.14 Million USD | 642.343% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | 10857.146% |
| Precipio, Inc. | -5.85 Million USD | 4931.881% |
| iSpecimen Inc. | -11.09 Million USD | 2647.955% |
| Natera, Inc. | -434.8 Million USD | 165.044% |
| Aspira Women's Health Inc. | -16.69 Million USD | 1794.488% |
| Standard BioTools Inc. | -74.65 Million USD | 478.818% |
| 23andMe Holding Co. | -666.7 Million USD | 142.419% |
| Castle Biosciences, Inc. | -57.46 Million USD | 592.134% |
| Personalis, Inc. | -108.29 Million USD | 361.145% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 419.628% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | 2943.152% |
| OpGen, Inc. | -32.66 Million USD | 965.696% |
| T2 Biosystems, Inc. | -50.07 Million USD | 664.75% |
| Myriad Genetics, Inc. | -112 Million USD | 352.509% |
| ICON Public Limited Company | 612.33 Million USD | 53.814% |
| NeoGenomics, Inc. | -87.96 Million USD | 421.492% |
| Star Equity Holdings, Inc. | -1.54 Million USD | 18369.38% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 66.533% |
| RadNet, Inc. | 3.04 Million USD | -9190.736% |
| MDxHealth SA | -43.1 Million USD | 756.172% |
| Psychemedics Corporation | -4.15 Million USD | 6908.137% |
| Illumina, Inc. | -1.16 Billion USD | 124.359% |
| Check-Cap Ltd. | -17.56 Million USD | 1709.802% |
| Twist Bioscience Corporation | -208.72 Million USD | 235.493% |
| DarioHealth Corp. | -59.42 Million USD | 575.895% |
| Fulgent Genetics, Inc. | -167.82 Million USD | 268.515% |
| Sera Prognostics, Inc. | -36.24 Million USD | 880.338% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | 2911.163% |
| OPKO Health, Inc. | -188.86 Million USD | 249.743% |
| Neogen Corporation | -9.42 Million USD | 3101.911% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | 2884.451% |
| Prenetics Global Limited | -62.72 Million USD | 550.881% |
| Mainz Biomed B.V. | -26.29 Million USD | 1175.498% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | 3663.18% |
| Trinity Biotech plc | -24.01 Million USD | 1277.492% |
| Neuronetics, Inc. | -30.18 Million USD | 1036.798% |
| Sotera Health Company | 51.37 Million USD | -450.471% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | 3663.18% |